Skip to main content
Defence Therapeutics Inc. logo

Defence Therapeutics Inc. — Investor Relations & Filings

Ticker · DTC ISIN · CA24463V1013 CSE Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2025-10-06 Regulatory Filings
Country CA Canada
Listing CSE DTC

About Defence Therapeutics Inc.

https://defencetherapeutics.com/

Defence Therapeutics Inc. is a biotechnology company focused on developing advanced cancer therapeutics by enhancing drug delivery. Its core technology is the proprietary Accum® platform, a precision intracellular drug-delivery system designed to overcome endosomal entrapment and ensure therapeutic agents reach their cellular targets. Accum® is applied to significantly boost the efficacy and safety of various biologics, including Antibody-Drug Conjugates (ADCs), Radiopharmaceuticals (Radioimmune Conjugates or rADCs), and vaccines. Preclinical models demonstrate that Accum® can increase the potency of enhanced therapies up to 60-fold, enabling safer and more effective first-line treatments. The company utilizes a licensing model for its ADC enhancement technology and actively develops novel radioimmune conjugate assets, aiming to transform existing and next-generation oncology treatments.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing Defence Therapeutics’ participation in an industry conference (CPHI Worldwide) and a networking event. It contains forward-looking statements but does not present financial results, regulatory filings, board changes, financing, dividends, or any formal report. It is not an Annual Report, Earnings Release, Management Discussion, or any other specific category. As it does not fit any specialized category, it falls into the general “Regulatory Filings” fallback bucket (RNS).
2025-10-06 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is a filled “Form 45-106F1 Report of Exempt Distribution,” a statutory Canadian securities filing under National Instrument 45-106. It is not an AGM or earnings report, nor a press release or investor presentation. It is a regulatory form required by securities law for a private placement (exempt distribution). This does not fit capital/financing update (which is typically a press announcement) or share issue notice (SHA) which is an announcement, not the formal regulatory form itself. Therefore, it is classified under Regulatory Filings (RNS).
2025-09-19 English
News release - English.pdf
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of Dr. Amie Phinney to the company’s Board of Directors, which directly relates to a change in the board/management. This matches the definition of Board/Management Information (Code: MANG).
2025-09-16 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing the allowance of a U.S. patent application by the USPTO. It contains forward‐looking statements and company background information but does not present financial results, management changes, dividends, share transactions, or other specific report types. It is not an Annual Report, Interim Report, earnings release, or any other defined filing category. Therefore, it falls under the general “Regulatory Filings” fallback category (RNS).
2025-06-09 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing a collaboration and future preclinical studies, with forward‐looking statements. It does not present financial results (ER/IR), regulatory filings of a specific form (e.g., 10‐K, IR, DIRS), governance items, capital market transactions, or AGM materials. It is a general announcement that does not fit any more specific category, so it falls into the fallback “Regulatory Filings” bucket.
2025-04-08 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Canadian NI 51-102F3 Material Change Report detailing the closing of a non-brokered private placement (fundraising), issuance of units, warrants, finder’s fees, and option grants. This is an update on company fundraising and change in capital structure, fitting our definition of a Capital/Financing Update (CAP).
2025-02-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.